Home › Research › Biomarkers
Recent breakthroughs in blood-based biomarkers of Alzheimer disease: opportunities and challenges in older adults
Adam H. Dyer, Helena Dolphin, Hanna‐Maria Roitto, A O'connor, Tomas James Welsh, Seán Kennelly. Age and Ageing, 2026-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Recent advances in Blood-Based Biomarkers (BBMs) are transforming the diagnostic landscape of Alzheimer Disease (AD), with plasma p-tau217 emerging as a highly accurate and scalable diagnostic marker of AD pathology. Across multiple analytical platforms, plasma p-tau217 has demonstrated consistently strong diagnostic performance for the detection of amyloid pathology. The interpretation of BBMs in older adults presents unique challenges due to the high prevalence of multimorbidity, chronic kidney disease, polypharmacy and frailty. Although these factors may influence absolute biomarker concentrations, current evidence suggests the diagnostic performance of p-tau217 remains largely preserved across diverse older populations when interpreted appropriately. Frailty may modify the relationship between AD pathology and clinical expression of mild cognitive impairment/dementia and may influence the absolute concentration of BBMs underscoring the importance of contextualising test results within a comprehensive assessment. Importantly, these factors should not preclude a clinical-biological diagnosis of AD. The clinical value of BBMs such as p-tau217 in older adults lies not in their use in isolation, but in their integration with a gerontologically attuned diagnostic pathway. Current evidence and international guidelines support the use of BBMs only in symptomatic older adults presenting to specialist services and not in asymptomatic individuals. This commentary reviews recent advances in BBM performance, emerging clinical guidelines, real-world evidence and potential diagnostic pitfalls relevant to older adults. We propose that incorporating BBMs within a Comprehensive Geriatric Assessment framework offers a pragmatic approach to achieving timely, accurate and equitable clinical-biological diagnosis whilst preserving the holistic, person centred principles of geriatric medicine.
What this study adds
Evidence grade: Low
Plasma p-tau217 showed consistently strong diagnostic performance for detecting amyloid pathology across multiple platforms, and its performance was largely preserved in older adults with multimorbidity, kidney disease, polypharmacy and frailty. Current evidence and guidelines support its use only in symptomatic older adults, so this is a diagnostic advance, not a treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dyer, A. H., Dolphin, H., Roitto, H., O'connor, A., Welsh, T. J., & Kennelly, S. (2026). Recent breakthroughs in blood-based biomarkers of Alzheimer disease: opportunities and challenges in older adults. Age and Ageing. https://doi.org/10.1093/ageing/afag213
Vancouver
Dyer AH, Dolphin H, Roitto H, O'connor A, Welsh TJ, Kennelly S. Recent breakthroughs in blood-based biomarkers of Alzheimer disease: opportunities and challenges in older adults. Age and Ageing. 2026. doi:10.1093/ageing/afag213. PMID: 42476554.
BibTeX
@article{dyer2026-42476554,
author = {Dyer, Adam H. and Dolphin, Helena and Roitto, Hanna‐Maria and O'connor, A and Welsh, Tomas James and Kennelly, Seán},
title = {{Recent breakthroughs in blood-based biomarkers of Alzheimer disease: opportunities and challenges in older adults}},
journal = {Age and Ageing},
year = {2026},
doi = {10.1093/ageing/afag213},
pmid = {42476554},
url = {https://doi.org/10.1093/ageing/afag213}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Across multiple analytical platforms, plasma p-tau217 has demonstrated consistently strong diagnostic performance for the detection of amyloid pathology.
- Frailty may modify the relationship between AD pathology and clinical expression of mild cognitive impairment/dementia and may influence the absolute concentration of BBMs underscoring the importance of contextualising test results within a comprehensive assessment.
Why it matters
Plasma p-tau217 showed consistently strong diagnostic performance for detecting amyloid pathology across multiple platforms, and its performance was largely preserved in older adults with multimorbidity, kidney disease, polypharmacy and frailty. Current evidence and guidelines support its use only in symptomatic older adults, so this is a diagnostic advance, not a treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Age and Ageing) |
| Journal's citation record | 2 / 4 | Age and Ageing: journal h-index 231 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Seán Kennelly: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Bristol: institution h-index 1,260 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42476554) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also in Biomarkers
137 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.